NYB (NYB Holdings) Research & Development: $ Mil (TTM As of Sep. 2025)


What is NYB Holdings Research & Development?

NYB Holdings NYB Research & Development is $ Mil as of Sep. 2025.

Research & Development is the aggregate amount of research and development expenses during the year. NYB Holdings's Research & Development for the six months ended in Sep. 2025 was $0.18 Mil. NYB Holdings does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Sep. 2025.

NYB Holdings  (NAS:NYB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

NYB Holdings Research & Development Related Terms

NYB Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for NYB Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NYB Holdings Research & Development Chart

NYB Holdings Annual Data
Trend Sep24 Sep25
Research & Development
3.09 0.18

NYB Holdings Semi-Annual Data
Sep24 Sep25
Research & Development 3.09 0.18

NYB Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $ Mil mean?
NYB Holdings (NYB) has a Research & Development of $ Mil as of Sep. 2025. Research and development expense is the total cost for research and development activities. View historical data on NYB Holdings and its competitors.
Is NYB Holdings' Research & Development too high?
NYB Holdings' current Research & Development is $ Mil.
How does NYB Holdings' Research & Development compare to ?
NYB Holdings' Research & Development of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on NYB Holdings and its competitors. NYB Holdings's current Research & Development is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NYB Holdings stock overvalued right now?
NYB Holdings (NYB) has a current Research & Development of $ Mil. The current Research & Development is $ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For NYB Holdings (NYB), the current Research & Development is $ Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NYB Holdings Business Description

Comparable Companies
Address 456 Alexandra Road, No. 04-07, Fragrance Empire Building, Singapore, SGP, 119962
NYB Holdings Ltd, along with its subsidiaries, is a pre-clinical biopharmaceutical company engaged in the research and development of therapeutics and nutraceuticals derived from biodiversity, including tropical medicinal plants with a history of traditional use. It focuses on discovering and developing natural compounds for applications in oncology and other chronic diseases, and also offers a consumer nutraceutical product line.